KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Capital Expenditures: 2017-2024

Historic Capital Expenditures for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $159,000.

  • Aquestive Therapeutics' Capital Expenditures rose 193.75% to $235,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $492,000, marking a year-over-year increase of 207.50%. This contributed to the annual value of $159,000 for FY2024, which is 84.02% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Capital Expenditures of $159,000 as of FY2024, which was down 84.02% from $995,000 recorded in FY2023.
  • Aquestive Therapeutics' 5-year Capital Expenditures high stood at $1.0 million for FY2022, and its period low was $159,000 during FY2024.
  • For the 3-year period, Aquestive Therapeutics' Capital Expenditures averaged around $726,000, with its median value being $995,000 (2023).
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 76.60% in 2021, then tumbled by 84.02% in 2024.
  • Aquestive Therapeutics' Capital Expenditures (Yearly) stood at $517,000 in 2020, then skyrocketed by 76.60% to $913,000 in 2021, then climbed by 12.16% to $1.0 million in 2022, then decreased by 2.83% to $995,000 in 2023, then plummeted by 84.02% to $159,000 in 2024.